Anaïs Schaschkow

Anaïs Schaschkow

Auto-generated profile, based on publicly available information

Anaïs Schaschkow

UMR DIATHEC, EA 7294, Centre Européen d'Etude du Diabète, Université de Strasbourg (UdS), Boulevard René Leriche, 67200 Strasbourg, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ECElodie Czuba
Elodie Czuba
MDMouhamadou Diop
Mouhamadou Diop
CMCarole Mura
Carole Mura
ASAnais Schaschkow
Anais Schaschkow
ALAllan Langlois
Allan Langlois
SSSeverine Sigrist
Severine Sigrist

1 June 2015 in Biomaterials
Verified
Journal Article
Closed access
ASA. Schaschkow
A. Schaschkow
CMC. Mura
C. Mura
WBW. Bietiger
W. Bietiger
CPC. Peronet
C. Peronet
ALA. Langlois
A. Langlois
EME. Maillard
E. Maillard

1 January 2020 in Acta Biomaterialia
Verified
Journal Article
Open access
ASAnaïs Schaschkow
Anaïs Schaschkow
SSSéverine Sigrist
Séverine Sigrist
CMCarole Mura
Carole Mura
JBJulien Barthes
Julien Barthes
NVNihal Engin VRANA
Nihal Engin VRANA
EMElisa Maillard
Elisa Maillard
Islet transplantation is one of the most efficient cell therapies used in clinics and could treat a large proportion of patients with diabetes. However, it is limited by the high requirement of pancreas necessary to provide the sufficient surviving islet mass in the hepatic tissue and restore normoglycaemia. Reduction in organ procurement requirements could be achieved by extrahepatic transplantation using a biomaterial that enhances islet survival and function. We report a plasma-supplemented hydroxypropyl methylcellulose (HPMC) hydrogel, engineered specifically using a newly developed technique for intra-omental islet infusion, known as hOMING (h-Omental Matrix Islet filliNG). The HPMC hydrogel delivered islets with better performance than that of the classical intrahepatic infusion. After the validation of the HPMC suitability for islets in vivo and in vitro, plasma supplementation modified the rheological properties of HPMC without affecting its applicability with hOMING. The biomaterial association was proven to be more efficient both in vitro and in vivo, with better islet viability and function than that of the current clinical intrahepatic delivery technique. Indeed, when the islet mass was decreased by 25% or 35%, glycaemia control was observed in the group of plasma-supplemented hydrogels, whereas no regulation was observed in the hepatic group. Plasma gelation, observed immediately post infusion, decreased anoïkis and promoted vascularisation. To conclude, the threshold mass for islet transplantation could be decreased using HPMC-Plasma combined with the hOMING technique. The simplicity of the hOMING technique and the already validated use of its components could facilitate its transfer to clinics. STATEMENT OF SIGNIFICANCE: One of the major limitations for the broad deployment of current cell therapy for brittle type 1 diabetes is the islets' destruction during the transplantation process. Retrieved from their natural environment, the islets are grafted into a foreign tissue, which triggers massive cell loss. It is mandatory to provide the islets with an 3D environment specifically designed for promoting isletimplantation to improve cell therapy outcomes. For this aim, we combined HPMC and plasma. HPMC provides suitable rheological properties to the plasma to be injectable and be maintained in the omentum. Afterwards, the plasma polymerises around the graft in vivo, thereby allowing their optimal integration into their transplantation site. As a result, the islet mass required to obtain glycaemic control was reduced by 35%.

16 January 2020 in Chemistry of Materials
Verified
Journal Article
Closed access
FXFangyun Xin
Fangyun Xin
YLYuhuan Li
Yuhuan Li
CFChangkui Fu
Changkui Fu
IJIbrahim Javed
Ibrahim Javed
XHXumin Huang
Xumin Huang
Ruirui QiaoRuirui Qiao
Ruirui Qiao

7 July 2015 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SDStéphanie Dal
Stéphanie Dal
NJNathalie Jeandidier
Nathalie Jeandidier
ASAnaïs Schaschkow
Anaïs Schaschkow
ASAnne‐Hélène Spizzo
Anne‐Hélène Spizzo
ESElodie Seyfritz
Elodie Seyfritz
SSSeverine Sigrist
Severine Sigrist

18 July 2016 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
ASA. Schaschkow
A. Schaschkow
CMCarole MURA
Carole MURA
SDS. Dal
S. Dal
ALA. Langlois
A. Langlois
ESE. Seyfritz
E. Seyfritz
EME. Maillard
E. Maillard
Exogenous insulin is the only treatment available for type 1 diabetic patients and is mostly administered by subcutaneous (SC) injection in a basal and bolus scheme using insulin pens (injection) or pumps (preimplanted SC catheter). Some divergence exists between these two modes of administration, since pumps provide better glycaemic control compared to injections in humans. The aim of this study was to compare the impacts of two modes of insulin administration (single injections of long-acting insulin or pump delivery of rapid-acting insulin) at the same dosage (4 IU/200 g/day) on rat metabolism and tissues. The rat weight and blood glucose levels were measured periodically after treatment. Immunostaining for signs of oxidative stress and for macrophages was performed on the liver and omental tissues. The continuous insulin delivery by pumps restored normoglycaemia, which induced the reduction of both reactive oxygen species and macrophage infiltration into the liver and omentum. Injections controlled the glucose levels for only a short period of time and therefore tissue stress and inflammation were elevated. In conclusion, the insulin administration mode has a crucial impact on rat metabolic parameters, which has to be taken into account when studies are designed.